Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens
Sara Gómez (1), Carlos Gamazo (1), Beatriz San Roman (1), Marta Ferrer (2), Maria Luisa Sanz (2) and Juan M. Irache (1)
(1) Adjuvant Unit, Department of Pharmaceutical Technology and Microbiology, University of Navarra, 31080 Pamplona, Spain
(2) Allergy Department, Clínica Universitaria, 31080 Pamplona, Spain
The aim of this study was to investigate the adjuvant properties of oral-administered Gantrez AN nanoparticles with ovalbumin (as allergen model) and, in some cases, lipopolysaccharide of Brucella ovis as immunomodulator.
For this purpose, BALB/c mice were administered by oral gavage with OVA nanoparticles and both Th1 and Th2 markers (IgG2a and IgG1, respectively) were enhanced. On the other hand, these carriers administered by oral route were able to protect a model of sensitized mice to ovalbumin from anaphylactic shock.
These results are highly suggestive for the valuable use of Gantrez nanoparticles in oral immunotherapy with allergens.
CITA DEL ARTÍCULO Vaccine. 2007 Jul 20;25(29):5263-71